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Background: Rheumatic joint pain is a common extraintestinal complication of 
inflammatory bowel disease (IBD). Because the high ratio of n-6 to n-3 fatty acids 
(FAs) of the Western diet might promote rheumatic disorders, we wanted to compare 
the effects of short-term duodenal administration of n-3 rich seal oil and n-6 rich soy 
oil, on IBD-related joint pain. Methods: Nineteen patients with IBD-related joint pain 
were included, 9 had Crohn’s disease and 10 had ulcerative colitis. Ten ml of seal oil (n 
= 10) or soy oil (n = 9) was self-administered through a nasoduodenal feeding tube 3 
times daily for 10 days. Results: Compared with soy oil treatment, seal oil significantly 
reduced the duration of morning stiffness (P = 0.024), number of tender joints (P = 
0.035), intensity of pain (P = 0.025) and the doctor’s scoring of rheumatic disease 
activity (P = 0.025) at end of the 10 days’ treatment period. Analysing the effects as 
area under the curve (area between the curve and baseline, zero) for the entire period 
from start of treatment until 6 months’ post treatment, suggested a long-lasting 
beneficial effect on joint pain of seal oil administration, while soy oil tended (not 
significantly) to aggravate the condition. Consistently, the serum ratios of n-6 to n-3 
FAs (P <<   0.01) and arachidonic acid to eicosapentaenoic acid (P <<   0.01) were reduced 
after treatment with seal oil. Conclusion: The results suggest distinctive differential 
prolonged effects on IBD-related joint pain of short-term duodenal administration of n-3 
rich seal oil (significant improvement) and n-6 rich soy oil (tendency to exacerbation). 
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Introduction 
Rheumatic arthritis is a commonly observed extraintestinal complication of 
inflammatory bowel disease (IBD) (1, 2). An even higher percentage of IBD-patients 
complain of joint pain (arthralgia) despite no objective clinical findings in the joints (3-
6). Several tender joints (polyarthralgia), morning stiffness and disturbed sleep are 
typical for patients with IBD-related joint pain. Conventional non-steroidal anti-
inflammatory drugs (NSAIDs) and selective cyclooxygenase-2 (COX-2) inhibitors have 
both been implicated in aggravation of experimental colitis (7, 8).  Consistently, 
conventional NSAIDs and possibly also selective COX-2 inhibitors might activate IBD 
(9, 10). These patients therefore have few options to control their joint pain. 
The high ratio of n-6 to n-3 fatty acids (FAs) of the western diet leads to a high 
ratio of arachidonic acid (20:4 n-6, AA) to eicosapentaenoic acid (20:5 n-3, EPA) in the 
blood and tissues, which may promote IBD and rheumatic disorders by facilitating the 
production of pro-inflammatory eicosanoids (11, 12). Of the n-3 FAs, only EPA, 
docosapentaenoic acid (22:5 n-3, DPA) and docosahexaenoic acid (22:6 n-3, DHA) are 
“marine” n-3 polyunsaturated fatty acids (PUFAs). The term “marine” denotes that 
EPA, DPA and DHA accumulates in the marine food chain and are present in high 
concentrations in seafood. Consistently, orally administered fish oil, rich in n-3 PUFAs, 
ameliorates IBD and rheumatoid arthritis (RA) after long-term treatment (2-12 months) 
(11, 13). In a recent pilot study we found a beneficial effect on IBD-related joint pain of 
duodenally administered n-3 PUFA rich seal oil already after 10 days (14). Seal oil 
contains slightly less EPA and DHA than fish oil, but approximately 4 fold more DPA 
(15). In fish oil, the n-3 PUFAs are mainly located in the middle position (sn-2) of the 
triacylglycerol (TAG) molecule, while they are located almost exclusively in the sn-
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1/sn-3 position of TAG from seal oil (16, 17). Pancreatic and lipoprotein lipases are 
both sn-1/sn-3 position specific (18). Therefore, both in the intestine and through the 
circulation, the n-3 PUFAs in TAG from seal oil may be more readily available for 
lipolysis than those in TAG from fish oil. Hence, lessons learned from studying 
absorption and metabolism of fish oil may not apply to seal oil.   
Based on the promising results of our uncontrolled pilot study (14), we wanted 
to do a controlled study comparing the effects of short-term duodenal administration of 
n-3 PUFA rich seal oil and n-6 rich soy oil, on IBD-related joint pain.
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Materials and methods 
Patients 
Nineteen patients with IBD-related joint pain were included in the study between 
January 2002 and June 2002 (Table I). Ten of the 19 patients had objective arthritis, 
defined as joint swelling, definite arthritis or anklyosing spondylitis. Two of the CD 
patients and one of the UC patients had been operated on with bowel resection. Fifteen 
of the 19 patients were on the following stable medications: 7 on 5-aminosalicylic acid 
(5-ASA), 3 on immune-suppressive medication with azathioprine, 2 on both 5-ASA and 
azathioprine, one on both 5-ASA, corticosteroid and central muscle-relaxing medicine, 
one on both 5-ASA and corticosteroid and one on a non-steroidal anti-inflammatory 
drug (NSAID). The remaining 4 patients received no medication. 
 
Study design 
The patients were randomly allocated to treatment with either seal oil (n = 10, CD:UC = 
5:5, 6 of 10 had arthritis) or soy oil (n = 9, CD:UC = 4:5, 4 of 9 had arthritis). After an 
overnight fast, a nasoduodenal feeding tube (Freka
®
 Feeding Tube, Fresenius Kabi, 
GmbH, Germany) was inserted by aid of fluoroscopy until its tip was located in the 
distal part of the duodenum. Ten ml of seal oil (Rieber Skinn A/S, Bergen, Norway) or 
soy oil (Mills DA, Oslo, Norway) was self-administered through the feeding tube before 
meals 3 times daily for 10 days. Fatty acid composition, levels of vitamin A and E and 
lipid peroxidation assessed by an in vitro method determining thiobarbituric acid 
reactive substances (TBARS) in the seal oil and soy oil are presented in Table II. Two 
of the patients refused using the feeding tube and preferred to drink the soy oil. The seal 
oil group thus received 2.0 grams of EPA, 0.9 grams of DPA and 2.2 grams of DHA per 
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day while the soy oil group received 14.9 grams of linoleic acid (18:2 n-6, LA) per day. 
The seal oil was a mixture of crude oil from harp seal (Phagophilus groenlandicus) and 
hooded seal (Cystophora cristata). The patients were assessed before and after the 
treatment period and then 1, 2, 4 and 6 months post treatment. No changes in diet or 
medication were made during the entire period from start of treatment until 6 months’ 
post treatment. 
 
Ethical considerations 
The study was approved by the Regional committee for medical research ethics 
and all patients gave written informed consent before inclusion.  
 
Methods 
The joint pain was quantified as follows: Duration of morning stiffness (min) 
during the last week. Number of palpation-tender, swollen and subjectively painful 
joints using a 28 joint count (19), with the addition of ankle joints and toes, toes scored 
as one. A 100 mm horizontal Visual Analogue Scale (VAS) ranging from 0 (very well) 
to 100 (very poor) was applied for doctor’s scoring of rheumatic disease activity, 
patient’s scoring of rheumatic disease activity and intensity of pain last week (20). The 
patients filled in a modified health assessment questionnaire (MHAQ) (21). The score in 
8 questions about functioning in daily life, with 4 alternative answers, were added and 
divided by 8, giving scores from 1 (very well) to 3 (very poor).  
IBD-index, a measure of IBD-activity, was evaluated by Harvey-Bradshaw 
simple index in CD (22) and Walmsley simple clinical colitis activity index in UC (23). 
These IBD-indexes consist of four clinical criteria; symptoms, physical signs, general 
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well being and extraintestinal complications. A score equal to or higher than 6 indicates 
an active disease. 
Faecal calprotectin concentration, also a measure of IBD-activity (24), was 
determined according to the Eurospital Calprest
®
, code 9031 (Medinor, Oslo, Norway), 
an enzyme-linked immunosorbent assay (ELISA) kit for determination of calprotectin 
in stools.  
Venous blood samples were collected in vials with no anticoagulant (gel vial). 
Serum FA composition was analysed by gas liquid chromatography (Trace GC 2000) 
according to previously described methods (14, 25), with some modifications; the FAs 
were esterified in 20 % boron trifluoride (BF3) in methanol (w/w) and biological sample 
parallels were analysed.  
Lipid peroxidation was analysed by an in vitro method determining TBARS in 
serum (26, 27).  
A simple self-constructed questionnaire about intake of marine food (n-3 
supplement and fish) was filled in by the patients at inclusion. There were 6 alternative 
answers for each meal (breakfast, lunch and dinner); every day = score 6, 3-4 days a 
week = score 5, 1-2 days a week = score 4, 3-4 days a month = score 3, 1-2 days a 
month = score 2 and never = score one.  
 
Statistics 
Data were analysed and displayed using the GraphPad Prism 4 (GraphPad 
Software Inc, San Diego, USA) statistical software package. Values were expressed as 
mean ± standard error of the mean (SEM). Effect of treatment was calculated as change 
(in absolute values) from baseline. Area under the curve (AUC) (area between the curve 
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and baseline, zero) for the entire period from start of treatment until 6 months post 
treatment was calculated by the trapezoid method. Normality of data was tested with 
Komogorov-Smirnoff test. Group differences were compared by unpaired Student’s t-
test (two-sided). Differences from baseline to end of treatment were evaluated by paired 
t-test. P values < 0.05 were regarded as statistically significant. 
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Results 
Patient status at baseline  
The soy oil group had a significantly higher intake of marine food compared with the seal oil 
group (9.8 ± 1.0 vs 7.0 ± 0.8, P = 0.04). Consistently, the soy oil group had lower ratios of n-6 
to n-3 FAs (P = 0.047) and AA to EPA (P < 0.01) in serum (Table III). As a result of the 
lower n-3 content in blood, the soy oil group had a lower joint pain- and IBD-activity 
compared with the seal oil group (significant for duration of morning stiffness; P <<   0.01 and 
number of tender joints; P = 0.045) (Table IV). Seven out of 10 patients receiving seal oil and 
3 out of 9 patients receiving soy oil had an IBD-index equal to 6 or higher, indicating active 
IBD (Table IV). Baseline faecal calprotectin values were low (Table IV). The patients were 
therefore regarded as having mild to moderately active IBD. Due to the significantly group 
differences at baseline, the effects of treatment were displayed as change from baseline. 
 
Joint pain  
At end of treatment 
At end of the 10 days’ treatment period, the patients receiving seal oil had significantly 
reduced duration of morning stiffness (P = 0.024), number of tender joints (P = 0.035), 
intensity of pain (P = 0.025) and doctor’s scoring of rheumatic disease activity (P = 0.025) 
compared with the patients receiving soy oil (Fig. 1a-d). Also compared with baseline, 
treatment with seal oil reduced the duration of morning stiffness (P = 0.015), intensity of pain 
(P <    0.01), doctor’s scoring of rheumatic disease activity (P <     0.01), MHAQ score (P <     0.01), 
number of subjectively painful joints (P = 0.03) and patient’s scoring of rheumatic disease 
activity (P <     0.01). Soy oil therapy tended (not significantly) to increase the joint pain (Fig. 
1a-e).
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During the entire observation period 
Comparison of AUC for the entire period from start of treatment until 6 months’ post 
treatment yielded significantly group differences for change from baseline of duration of 
morning stiffness (P = 0.02), doctor’s scoring of rheumatic disease activity (P = 0.03) and 
MHAQ score (P = 0.03) (Fig. 1a, b, e). The seal oil group’s AUC for intensity of pain (P = 
0.02), doctor’s scoring of rheumatic disease activity (P =     0.01) and MHAQ score (P =      0.02) 
was significantly negative (i.e., reduced joint pain), while the soy oil group’s AUC was (not 
significantly) positive (i.e., increased pain) (Fig. 1a-e). 
 
Fatty acid composition 
Group comparisons 
There were significant group differences at end of treatment (calculated as change from 
baseline) for ∑ n-6 FAs (P <   0.01), LA (P <   0.01), 20:3 n-6 (P <   0.01), ∑ n-3 FAs (P <   0.01), 
EPA (P <<    0.01), DPA (P = 0.01), DHA (P = 0.01), and ratios of n-6 to n-3 FAs (P <<     0.01) 
and AA to EPA (P <<    0.01) (Table III, Figure 2).  
 
Compared to baseline 
Compared to baseline, reduced ratios of AA to EPA, n-6 to n-3 FAs and ∑ n-6 FAs (LA and 
20:3 n-6) and increased ∑ n-3 FAs (EPA, DHA and DPA) were observed at end of treatment 
with seal oil (Table III, Figure 2). Increased level of n-6 FAs (mainly LA) was observed at 
end of treatment with soy oil (Table III).  
 
IBD-activity 
Comparison of AUC for the entire period from start of treatment until 6 months post treatment 
yielded no significant group differences for IBD-index (Figure 3). Compared with baseline, a 
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significant improvement in IBD-index was observed at end of treatment with seal oil (P = 
0.02).  
 
Adverse effects  
No significant change in TBARS was seen (data not shown). Soy oil treatment caused nausea 
in two patients and reduced food intake in one of these two patients. One patient experienced 
burping and abdominal pain during treatment with seal oil. These adverse effects were mild 
and did not result in treatment termination.
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Discussion 
Compared with soy oil, duodenal administration of seal oil for 10 days significantly improved 
IBD-related joint pain, and the effect persisted several months post treatment. While 
improvement was seen after treatment with seal oil, soy oil tended (not significantly) to 
deteriorate the condition. The present study confirmed the promising results from our pilot 
study. Hence, both studies suggest that short-term duodenal administration of seal oil is able 
to ameliorate IBD-related joint pain substantially. 
Most nutritional research concerning IBD and rheumatic disorders have focused on the 
effects of orally administered fish oil, either in form of capsules or liquid oil (11, 13). In fish 
oil, the n-3 PUFAs are mainly located in the middle position (sn-2) of the TAG molecule, 
while they are located almost exclusively in the sn-1/sn-3 position of TAG from seal oil (16, 
17). Digestion of TAG in the duodenum by pancreatic lipases specifically acting on the sn-
1/sn-3 positions yields two free FAs and 2-monoacylglycerol which are taken up by the 
enterocyte, followed by re-esterification into TAG and incorporation into chylomicrons 
designated for the lymphatic route (18). During digestion of TAG in the duodenum it has been 
estimated that approximately 75% of the FAs in the sn-2 position remain in this position (28). 
The resultant chylomicrons reflect the dietary TAGs with respect to both the fatty acid 
composition and location of the n-3 PUFAs on the TAG molecule (17). This implies a general 
conservation of the FAs in the sn-2 position, which is important considering the possible 
advantages of structurally different oils and in tailor making fats with particular TAG-
structures and maintaining the location of FAs in specific positions following absorption (14, 
29). Lipoprotein lipases in the circulation also digest TAG by specifically acting on the sn-
1/sn-3 positions (18).The rapid effect on joint pain from seal oil treatment might therefore in 
part be explained by readily available free n-3 PUFAs (EPA) competing with AA as substrate 
for eicosanoid production as suggested by the decreased ratio of AA to EPA in serum (P <<     
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0.01), resulting in a shift to a less pro-inflammatory eicosanoid profile. Eicosanoid production 
was not assessed in the present study, however a decreased production of prostaglandin E2 
(PGE2) was observed in rats fed EPA or DHA in the sn-1/sn-3 position but not in the sn-2 
position of structured TAG (30). Also, seal oil is superior to fish oil in reducing AA content in 
plasma and liver phospholipids (17, 31). Thus, the different positional distribution of n-3 FAs 
on the TAG molecule in seal and fish oils may be important in order to achieve an “optimal” 
eicosanoid profile.  
Duodenal administration of the oils might ensure not only rapid absorption by yielding 
a much higher bolus of n-3 PUFAs into the circulation as compared to drinking, as the former 
avoids the mixing and dilution in the stomach, but also correct dosing and avoiding of the 
smell and taste of the crude seal oil. Duodenal administration and sn-1/sn-3 distribution of n-3 
FAs may therefore partly explain the rapid joint pain ameliorating effect of seal oil. The much 
less marked effect on IBD-activity by seal oil, consistent with the pilot study (14), suggests 
that the intestines and the joints are affected by different disease mechanisms. As also 
suggested by former studies, the joint pain was largely independent of IBD-activity (3, 14), 
thus the seal oil probably acted directly on the joints and not indirectly through any 
improvement of IBD-activity. Due to the rapid relief of joint pain, duodenally administrated 
seal oil might represent a nutritional treatment of joint pain/arthritis without the adverse 
gastrointestinal effects of NSAIDs and selective COX-2 inhibitors. In this study with mild to 
moderately active IBD-patients, the experienced adverse effects were mild, however before 
recommending widespread use of seal oil in more active IBD, the potential of an increased 
lipid peroxidation should be addressed.  
Increased intake of n-6 FAs and a concomitant increased ratio of n-6 to n-3 FAs have 
been correlated to increased occurrence of CD (32). In a recent study comparing different 
enteral feeds for the treatment of active CD, remission rates fell with increasing soy oil 
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content (33). The higher (not significant) ratio of AA to EPA after treatment with soy oil, 
might explain the tendency (not significant) to deterioration of joint pain. This tendency is 
worrying in view of the wide use of soy oil in the western diet. Thus, it may not be the fat 
content but rather the type of fat that is important, particularly for patients dependent on 
enteral or parenteral nutrition.  
The major limitation of the present study was that unfortunately, in spite of random 
allocation, the treatment groups differed significantly at baseline. Consistent with a lower 
intake of marine food in the seal oil group (P = 0.04), the ratio of AA to EPA in serum was 
almost twice higher in this group (P < 0.01). Interestingly, the low ratio of n-6 to n-3 FAs in 
the background diet and the consequent low ratio of AA to EPA in the blood, might explain 
the unbalances in joint pain and IBD activity between the groups. Also, the small number of 
patients having different rheumatic problems might be a reason for the group differences, 
even though the data were normally distributed. A consequence of the group differences for 
our study could be that the seal oil group would be easier to treat simply because this patient 
group had more of what we aimed to treat (the IBD-related joint pain). However, it might not 
be clinically relevant to treat the patients in the soy oil group based on their low disease 
activity. Therefore, instead of philosophicating about what would happen if the treatment 
groups had been opposite, we may conclude that seal oil treatment had a positive health effect 
in those patients that really suffered from joint pain. The effect of treatment was similar in the 
CD and UC patients (data not shown), justifying pooling the two patient groups to one IBD 
group. The IBD-indexes for CD (22) and UC (23) are based on relatively similar 
questionnaires of IBD-activity. We therefore pooled the CD and UC index-scores in one IBD-
index. High oral doses of n-3 PUFA for 6 weeks are required to ensure maximum FA 
incorporation into cell membranes of red blood cells (34). In view of the short-term treatment, 
we reported serum FA levels only, which reflect the dietary FA intake (35). 
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In conclusion, a distinctive differential prolonged effect on IBD-related joint pain was 
observed after short-term (10 days) duodenal administration of seal oil or soy oil. While seal 
oil improved IBD-related joint pain significantly, soy oil tended (not significantly) to 
exacerbate the condition. Consistently, ratios of n-6 to n-3 FAs and AA to EPA in serum were 
significantly decreased after treatment with seal oil and tended to increase (not significantly) 
after treatment with soy oil.
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Table I: Characteristics of the patients 
Disease n Male Female Range age (yrs) Mean age (yrs) 
CD 9 4 5 21 - 44 33.1 
UC 10 4 6 16 - 55 40.8 
CD = Crohn’s disease, UC = ulcerative colitis and n = number of patients. 
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Table II: Major fatty acids, vitamins A and E and TBARS 
 Seal oil Soy oil 
 g/100 g g/100g 
 saturated 12.9 13.4 
16:1n-7 11.6 n.d 
18:1n-9 16.3 17.5 
20:1n-9 7.5 0.2 
 monoenes 47.6 19.0 
18:2n-6 1.4 49.7 
20:4n-6 0.4 n.d 
 -6 1.8 49.7 
18:3n-3 0.7 5.5 
20:5n-3 6.6 n.d 
22:5n-3 3.1 n.d 
22:6n-3 7.4 n.d 
 -3 21.0 5.5 
n-6/n-3 0.1 9.0 
Sum vitamin A 1.4  mg/100g n.d 
-tocopherol 5.4 mg/100g 17.1 mg/100g 
TBARS 15.3 nmol/g DW n.d 
Sum vitamin A  = all-trans retinol + 13-cis retinol +  3-Dehydroretinol. TBARS = thiobarbituric acid 
reactive substances. n.d  = not detected. DW = dry weight.
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Table III: Serum fatty acid composition (%) before and after treatment with seal oil or soy oil  
Fatty acid Seal oil group 
Before             After 
P-value Soy oil group 
Before            After 
P-value 
∑ saturated 29.5 ± 1.0 29.0 ± 1 0.64 28.4 ± 0.7 27.4 ± 0.7 0.18 
∑ monoenes 24.2 ± 1.1 23.3 ± 1.1 0.61 22.7 ± 1.4 21 ± 1.1 0.07 
18:2 n-6† 32.2 ± 1.8 29.6 ± 1.5 0.04 33.8 ± 2.5 37.9 ± 1.9 0.02 
20:3 n-6† 1.6 ± 0.1 1.0 ± 0.1 <<    0.01 1.4 ± 0.1 1.3 ± 0.1 0.45 
20:4 n-6* 5.6 ± 0.4 5.5 ± 0.3 0.59 4.4 ± 0.3 4.6 ± 0.4 0.45 
∑ n-6† 39.9 ± 1.8 36.9 ± 1.4 0.02 34.6 ± 4.6 38.5 ± 4.9 0.02 
18:3 n-3* 0.59 ± 0.04 0.54 ± 0.04 0.27 0.9 ± 0.1 0.9 ± 0.1 0.54 
20:5 n-3† 1.1 ± 0.3 4.2 ± 0.4 <<    0.01 1.7 ± 0.4 1.3 ± 0.3 0.28 
22:5 n-3† 0.50 ± 0.03 0.82 ± 0.04 <<    0.01 0.7 ± 0.2 0.53 ± 0.03 0.29 
22:6 n-3† 2.2 ± 0.3 4.0 ± 0.3 <<    0.01 3.6 ± 0.9 2.7 ± 0.2 0.31 
∑ n-3† 4.2 ± 0.5 9.4 ± 0.7 <<    0.01 7.1 ± 1.5 5.5 ± 0.6 0.31 
n-6/n-3*† 10.0 ± 0.6 4.0 ± 0.3 <<    0.01 7.2 ± 1.1 8.6 ± 0.8 0.15 
20:4 n-6/20:5 n-3*† 7.0 ± 0.8 1.5 ± 0.1 <<    0.01 3.8 ± 0.7 4.9 ± 0.8 0.21 
Data expressed as % of total fatty acids (FAs). Percent identified FAs ranged between 94.9-99.3 %.  
P-values indicate change from before to after treatment in the seal or soy oil groups. * = significant group 
difference at baseline. † = significant group difference after treatment.
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Table IV: Joint pain and IBD-activity at baseline  
 Seal oil group      Soy oil group P-value 
Morning stiffness (min)* 68.5 ± 13.7 14.5 ± 4.7 <<    0.01 
Tender joints (number)* 7.4 ± 2.2 1.9 ± 0.4 0.045 
Swollen joints (number) 1.2 ± 0.6 0.3 ± 0.2 0.18 
Painful joints (number) 10.6 ± 3.2 4.5 ± 2.2 0.16 
DocVAS (mm) 31.1 ± 5.6 15.6 ± 6.0 0.08 
PainVAS (mm) 47.8 ± 7.7 33.3 ± 9.9 0.27 
TotVAS (mm) 48.5 ± 8.2 35.3 ± 10.9 0.34 
MHAQ (score) 1.320 ± 0.077 1.381 ± 0.150 0.70 
IBD-index (score) 6.5 ± 1.1 4.8 ± 0.8 0.22 
Calprotectin (mg/kg) 7.3 ± 5.9 4.6 ± 4.6 0.73 
DocVAS = doctor’s scoring of rheumatic disease activity. PainVAS = intensity of pain last week. TotVAS = 
patient’s scoring of rheumatic disease activity. MHAQ = modified health assessment questionnaire. IBD-index = 
sum of Harvey-Bradshaw simple index for Crohn’s disease and Walmsley simple clinical colitis activity index 
for ulcerative colitis. * = significant group difference at baseline.
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Fig. 1a-e. Change in joint pain from baseline for the entire period from start of treatment with seal oil (○) or soy 
oil (●) until 6 months’ post treatment.  Thick horizontal line indicates the treatment period of 10 days. MHAQ = 
modified health assessment questionnaire. AUC = area under the curve (area between the curve and baseline, 
zero). * = significant group differences in AUC for the entire period from start of treatment until 6 months post 
treatment. † = significant group difference at end of treatment.  
 
Fig. 2. Change in serum ratio of arachidonic acid (20:4 n-6, AA) to eicosapentaenoic acid (20:5 n-3, EPA) from 
baseline to end of treatment with seal oil (○) or soy oil (●).  * = significant group difference (P <<    0.01) and † = 
significant change from baseline (P <<    0.01). 
 
Fig. 3. Change in IBD-index (sum of Harvey-Bradshaw simple index for Crohn’s disease and Walmsley simple 
clinical colitis activity index for ulcerative colitis) during treatment with seal oil (○) or soy oil (●) and 6 months 
post treatment. Thick horizontal line indicates the treatment period of 10 days. AUC = area under the curve (area 
between the curve and baseline, zero). 
